| ISSN |
2308-3840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
©The Author(s) 2024. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Urology & Nephrology |
| Manuscript Type |
Meta-Analysis |
| Article Title |
Incidence and predictors of hypocalcemia in end-stage renal disease patients on denosumab therapy: A systematic review and meta-analysis
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Abdul Hannan Siddiqui, Misbah Shaikh, Afia Salman, Muhammad Ahmed Ali Fahim, Fizzah Batool, Tahreem Mari, Sarah Musani, Muneeb Fareed, Rooma Rehan, Amna Hassni, Urooj Nizami, Ayesha Amir, Abdul Moeed and Salim R Surani |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Abdul Moeed, Doctor, MBBS, Academic Editor, Doctor, Doctor, Researcher, Department of Internal Medicine, Dow University of Health Sciences, Dow Medical College, Karachi 74200, Sindh, Pakistan. abdul.moeed19@dmc.duhs.edu.pk |
| Key Words |
Denosumab; End-stage renal disease; Hypocalcemia; Parathyroid hormone; Dialysis |
| Core Tip |
Denosumab is a monoclonal antibody that inhibits receptor activator of nuclear factor kappa-Β-ligand and prevents bone resorption, making it useful for treating osteoporosis. Although denosumab has an acceptable safety profile, it is known to cause hypocalcemia in patients with renal insufficiency leading to it being contraindicated in patients with hypocalcemia. Such patients may experience muscle and joint pain. To date, very few randomized controlled trials have explored the safety of this drug in patients with end-stage renal disease (ESRD) or on dialysis. This meta-analysis thus appraises the safety profile of denosumab in ESRD patients. |
| Publish Date |
2024-09-13 09:40 |
| Citation |
<p>Siddiqui AH, Shaikh M, Salman A, Fahim MAA, Batool F, Mari T, Musani S, Fareed M, Rehan R, Hassni A, Nizami U, Amir A, Moeed A, Surani SR. Incidence and predictors of hypocalcemia in end-stage renal disease patients on denosumab therapy: A systematic review and meta-analysis. <i>World J Meta-Anal</i> 2024; 12(3): 97256</p> |
| URL |
https://www.wjgnet.com/2308-3840/full/v12/i3/97256.htm |
| DOI |
https://dx.doi.org/10.13105/wjma.v12.i3.97256 |
